MARKETSPERPSLIVE36SOCIAL
RESEARCH
Cash
Browse
Live36
Portfolio
Search
Social
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science
Browse
Live36
Portfolio
Search
Social
Product
Perpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatory
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science
All markets
2026 Mega IPOs
Companies
CEOs
IPOs
KPIs
M&A
Product launches
Industries
Healthcare
Technology
Markets
Foreign Exchange
Indices
Interest Rates
Match Ups

Healthcare

Industries

FDA decision: Gedatolisib by Celcuity Inc. (July 2026)

Full Approval
1.28x
Denied (CRL Issued)
9.41x
$4,538 vol5 markets
Industries

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes
1.22x
No
3.80x
$30 vol1 market
Industries

FDA decision: Zidesamtinib by Nuvalent (this year)

Yes
1.25x
No
3.40x
$0 vol1 market
Industries

FDA decision: Venglustat by Sanofi (this year)

Yes
1.15x
No
4.51x
$0 vol1 market
Industries

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.31x
No
2.98x
$0 vol1 market
Industries

FDA decision: Rusfertide by Protagonist Therapeutics (this year)

Yes
1.09x
No
6.29x
$54 vol1 market
Industries

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes
1.57x
No
2.19x
$107 vol1 market
Industries

FDA decision: Iberdomide by Celgene (this year)

Yes
1.40x
No
2.66x
$13 vol1 market
Industries

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)

Yes
1.44x
No
2.59x
$90 vol1 market
Industries

FDA decision: Brepocitinib by Priovant Therapeutics (this year)

Yes
1.22x
No
3.80x
$45 vol1 market
Industries

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)

Yes
1.05x
No
9.41x
$9 vol1 market
Industries

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes
1.29x
No
3.18x
$64 vol1 market
Industries

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.06x
No
8.56x
$18 vol1 market
Industries

FDA decision: Atacicept by Vera Therapeutics (in July 2026)

Yes
1.08x
No
6.74x
$748 vol1 market
Industries

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.23x
No
3.80x
$458 vol1 market